HemaMax Therapies
Therapies under development for HemaMax™:
Treatment of Hematopoietic Syndrome related to ARS as a result of exposure to Ionizing Radiation, under Animal Rule CFR 601, subpart H.
Additional Indications under development include:
Prevention of the hematological toxicity associated with cancer treatments, namely radiation and chemotherapy. In this indication, it is anticipated that use of HemaMax will concomitantly provide anti-tumor effects over and above that of the primary therapy, in addition to preventing severe hematological toxicity generally caused by the cancer treatment. For this indication, HemaMax would serve as a hematological adjuvant cancer therapy.
Treatment of the myelosuppression caused by cancer treatments, namely radiation and chemotherapy.
|

For use in hematopoietic stem cell transplantation, currently used to treat lymphomas and leukemias. It is anticipated that use of HemaMax along with a small number of HemaMax receptor positive hematopoietic stem cells can obviate the need for a conventional peripherally mobilized hematopoietic cellular transplant.
For use in the treatment of the bone marrow failure associated with aplastic anemia.
|